RESUMO
The Bacille Calmette-Guérin (BCG) vaccine comprises a family of genetically different strains derived by the loss of genomic regions (RDs) and other mutations. In BCG Moreau, loss of RD16 inactivates rv3405c * , encoding a transcriptional repressor that negatively regulates the expression of Rv3406, an alkyl sulfatase. To evaluate the impact of this loss on the BCG and host cell viability and the cytokine profile, THP-1 cells were infected with BCG Moreau (harbouring the empty vector) and a complemented strain carrying a functional copy of rv3405c. Viability of the host cells and bacteria as well as the pattern of cytokine secretion were evaluated. Our results show that the viability of BCG Moreau is higher than that of the complemented strain in an axenic medium, suggesting a possible functional gain associated with the constitutive expression of Rv3406. Viability of the host cells did not vary significantly between recombinant strains, but differences in the profiles of the cytokine secretion (IL-1ß and IL-6) were observed. Our results suggest an example of a functional gain due to gene loss contributing to the elucidation of the impact of RD16 on the physiology of BCG Moreau.
Assuntos
Vacina BCG/farmacologia , Sobrevivência Celular/genética , Citocinas/efeitos dos fármacos , Mutação com Ganho de Função/genética , Macrófagos/microbiologia , Mycobacterium bovis/genética , Transcrição Gênica/genética , Vacina BCG/genética , Sobrevivência Celular/efeitos dos fármacos , Citocinas/genética , Mutação com Ganho de Função/efeitos dos fármacos , Humanos , Mycobacterium bovis/fisiologia , Fatores de Tempo , Transcrição Gênica/efeitos dos fármacos , Células Tumorais Cultivadas/efeitos dos fármacos , Células Tumorais Cultivadas/microbiologiaRESUMO
Tuberculosis has great public health impact with high rates of mortality and the only prophylactic measure for it is the Mycobacterium bovis bacillus Calmette-Guérin (BCG) vaccine. The present study evaluated the release of cytokines [interleukin (IL)-1, tumour necrosis factor and IL-6] and chemokines [macrophage inflammatory protein (MIP)-1α and MIP-1ß] by THP-1 derived macrophages infected with BCG vaccine obtained by growing mycobacteria in Viscondessa de Moraes Institute medium medium (oral) or Sauton medium (intradermic) to compare the effects of live and heat-killed (HK) mycobacteria. Because BCG has been reported to lose viability during the lyophilisation process and during storage, we examined whether exposing BCG to different temperatures also triggers differences in the expression of some important cytokines and chemokines of the immune response. Interestingly, we observed that HK mycobacteria stimulated cytokine and chemokine production in a different pattern from that observed with live mycobacteria.
Assuntos
Quimiocinas/metabolismo , Macrófagos/imunologia , Viabilidade Microbiana/imunologia , Mycobacterium bovis/classificação , Linhagem Celular , Quimiocina CCL3/metabolismo , Quimiocina CCL4/metabolismo , Citocinas/metabolismo , Humanos , Interleucina-1/metabolismo , Interleucina-6/metabolismo , Macrófagos/classificação , Macrófagos/efeitos dos fármacos , Mycobacterium bovis/imunologia , Fator de Necrose Tumoral alfa/metabolismo , Vacinas de Produtos InativadosRESUMO
Tuberculosis has great public health impact with high rates of mortality and the only prophylactic measure for it is the Mycobacterium bovisbacillus Calmette-Guérin (BCG) vaccine. The present study evaluated the release of cytokines [interleukin (IL)-1, tumour necrosis factor and IL-6] and chemokines [macrophage inflammatory protein (MIP)-1α and MIP-1β] by THP-1 derived macrophages infected with BCG vaccine obtained by growing mycobacteria in Viscondessa de Moraes Institute medium medium (oral) or Sauton medium (intradermic) to compare the effects of live and heat-killed (HK) mycobacteria. Because BCG has been reported to lose viability during the lyophilisation process and during storage, we examined whether exposing BCG to different temperatures also triggers differences in the expression of some important cytokines and chemokines of the immune response. Interestingly, we observed that HK mycobacteria stimulated cytokine and chemokine production in a different pattern from that observed with live mycobacteria.
Assuntos
Humanos , Quimiocinas , Macrófagos/imunologia , Viabilidade Microbiana/imunologia , Mycobacterium bovis/classificação , Linhagem Celular , Citocinas , Interleucina-1 , Macrófagos/classificação , Macrófagos/efeitos dos fármacos , Mycobacterium bovis/imunologia , Fator de Necrose Tumoral alfa , Vacinas de Produtos InativadosRESUMO
The bacillus Calmette-Guérin (BCG) vaccine is the only licensed vaccine for human use against tuberculosis (TB). Although controversy exists about its efficacy, the BCG vaccine is able to protect newborns and children against disseminated forms of TB, but fails to protect adults against active forms of TB. In the last few years, interest in the mucosal delivery route for the vaccine has been increasing owing to its increased capacity to induce protective immune responses both in the mucosal and the systemic immune compartments. Here, we show the importance of this route of vaccination in newly developed vaccines, especially for vaccines against TB.
Assuntos
Vacina BCG/administração & dosagem , Tuberculose Pulmonar/prevenção & controle , Vacinação/métodos , Administração Oral , Adolescente , Adulto , Vacina BCG/história , Vacina BCG/imunologia , Criança , História do Século XX , História do Século XXI , Humanos , Imunidade nas Mucosas , Memória Imunológica , Recém-Nascido , Tecido Linfoide/imunologiaRESUMO
The bacillus Calmette-Guérin (BCG) vaccine is the only licensed vaccine for human use against tuberculosis (TB). Although controversy exists about its efficacy, the BCG vaccine is able to protect newborns and children against disseminated forms of TB, but fails to protect adults against active forms of TB. In the last few years, interest in the mucosal delivery route for the vaccine has been increasing owing to its increased capacity to induce protective immune responses both in the mucosal and the systemic immune compartments. Here, we show the importance of this route of vaccination in newly developed vaccines, especially for vaccines against TB.
